Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Polypharmacy in Older Adults Elderly: What Medication to Discontinue

Polypharmacy is certainly a problem in the elderly population. Forgetfulness, and drug and dose confusion can lead to multiple problems; in addition, over time, cognitive deterioration will make complicated drug management schemes even more difficult for patients to handle. 

Polifarmacia en adultos mayores ¿Qué medicación no podemos suspender?

Aware of this problem, physicians often try to simplify schemes by discontinuing drugs, but what should we discontinue when it means risking patient health? This study recently presented at JAMA at least clarifies what drug NEVER to discontinue. 

The study looked at a cohort of 29,047 patients older than 65 who were on statins, hypertensive medication, antidiabetics and antiplatelets between 2013 and 2015.

This study was particularly focused on patients discontinuing statins. These were matched using propensity score to be compared against patients who stayed on all medication (statins and the rest). 

Of the total population of nearly 30,000 patients, 20% discontinued statins and kept taking the rest of prescribed medication; the rest of the population kept taking all drugs and served as control group. 

Patients discontinuing statins had higher risk of hospitalization for cardiac failure (HR 1.24; CI 95%, 1.07-1.43), any adverse cardiovascular event (HR, 1.14; CI 95%, 1.03-1.26), all cause death (HR, 1.15; CI 95%, 1.02-1.30) and emergency hospitalization for any cause (HR, 1.12; CI 95%, 1.05-1.19). 


Read also: Myocarditis and mRNA COVID-19 Vaccines: New Information from the CDC.


Comorbidities rate resulted very similar in both groups, which makes it hard to believe doctors would discontinue statins because of patient frailty. 

Conclusion

Patients receiving polypharmacy who for whatever reason discontinue statins (while still taking the rest of prescribed drugs) present increased risk of fatal and non-fatal events. 

rea-2021-oi-210393-1622769937-85783

Original Title: Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy.

Reference: Federico Rea et al. JAMA Netw Open. 2021 Jun 1;4(6):e2113186. doi: 10.1001/jamanetworkopen.2021.13186.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous closure of paravalvular leaks in high-risk patients: clinical outcomes and the impact of residual leak

Paravalvular leak (PVL) is a relatively frequent complication following valve replacement (overall incidence 5–18%; 2–10% in the aortic position and 7–17% in the mitral...

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...